BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.

Autor:	Louw A; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, Australia; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia., Panou V; Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark; Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark., Szejniuk WM; Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark., Meristoudis C; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark., Chai SM; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia., van Vliet C; Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia., Lee YCG; Institute for Respiratory Health, Perth, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia; Medical School, University of Western Australia, Perth, Australia., Dick IM; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia., Firth T; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia., Lynggaard LA; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark., Asghari AB; Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark., Vyberg M; Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark., Hansen J; Danish Cancer Society, Research Center, Copenhagen, Denmark., Creaney J; Institute for Respiratory Health, Perth, Australia; National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia. Electronic address: jenette.creaney@uwa.edu.au., Røe OD; Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark; Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2022 Jul; Vol. 17 (7), pp. 921-930. Date of Electronic Publication: 2022 Apr 27.
DOI:	10.1016/j.jtho.2022.04.008
Abstrakt:	Introduction: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemetrexed therapy. Methods: PM cases (n = 114) from Aalborg, Denmark, were stained for BAP1 on tissue microarrays. Demographic, clinical, and survival data were extracted from registries and medical records. Surgical cases were excluded. BAP1 status was associated with overall survival (OS) by Cox regression and Kaplan-Meier methods. Results were validated in an independent cohort from Perth, Australia (n = 234). Results: BAP1 loss was found in 62% and 60.3% of all Danish and Australian samples, respectively. BAP1 loss was an independent predictor of OS in multivariate analyses corrected for histological subtype, performance status, age, sex, and treatment (hazard ratio = 2.49, p < 0.001, and 1.48, p = 0.01, respectively). First-line platinum and pemetrexed-treated patients with BAP1 loss had significantly longer median survival than those with retained BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001) and Australian cohorts (19.6 versus 11.1 mo, p < 0.01). Survival in patients with BAP1 retained and treated with platinum and pemetrexed was similar as in those with best supportive care. There was a higher OS in patients with best supportive care with BAP1 loss, but it was significant only in the Australian cohort (16.8 versus 8.3 mo, p < 0.01). Conclusions: BAP1 is a predictive biomarker for survival after first-line combination platinum and pemetrexed chemotherapy and a potential prognostic marker in PM. BAP1 in tumor is a promising clinical tool for treatment stratification. (Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu